Form 4: Relmada Therapeutics CEO Sergio Traversa Receives and Forfeits Stock Options

Relmada Therapeutics CEO Sergio Traversa received options for 122,358 shares and immediately forfeited them to the company for reallocation to other employees.

Summary

• On May 24, 2024, Relmada Therapeutics CEO Sergio Traversa received options for 122,358 additional shares of the company's common stock under the terms of a previous option award granted on December 15, 2023.
• These options became available due to expirations, cancellations, forfeitures, and terminations of other outstanding awards under the company's 2021 Equity Incentive Plan.
• On the same day, Traversa voluntarily forfeited these 122,358 shares back to the company.
• The forfeited shares will be allocated to holders of similar awards who are not executive officers or directors of the Issuer.
• Following these transactions, Traversa directly owns 306,239 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CEO receiving and forfeiting options doesn't inherently indicate a positive or negative outlook, but the reallocation to other employees could be seen as a positive move for employee morale.

Positives

• The reallocation of forfeited options to non-executive employees could improve morale and align incentives within the company.
• The forfeiture demonstrates a commitment to equitable distribution of equity incentives.

Industry Context

Stock option grants and forfeitures are common practices in publicly traded companies to incentivize and retain employees. The reallocation of forfeited options to non-executive employees is a positive sign of equitable compensation practices.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, similar to companies like Amgen, Biogen, and Gilead Sciences.
• Forfeiture and reallocation of options are less common but can occur due to employee departures or, as in this case, a voluntary decision to redistribute equity.

Stakeholder Impact

• Shareholders may view the reallocation of options as a positive sign of equitable compensation practices.
• Employees who receive the reallocated options will benefit from the increased equity ownership.

Key Dates

Keywords

Relmada Therapeutics, Sergio Traversa, stock options, equity incentive plan, forfeiture, RLMD, CEO, options